Clinical Trials Logo

Filter by:
NCT ID: NCT06098170 Active, not recruiting - Clinical trials for Spinal Cord Injuries

Acceptance and Commitment Therapy for Chronic Pain in SCI: Development and Testing of an eHealth Program

Start date: November 15, 2023
Phase: N/A
Study type: Interventional

This study will test the newly-developed My spinal cord injury (SCI) Toolkit program in two formats - unguided use of the program and use supported by a coach. These two active treatment formats will be compared to treatment as usual (waitlist control) in adults with chronic pain and SCI. Hypotheses include: - Treatment adherence, participant satisfaction, and perception of positive change will be high and drop-out rates low for both treatments but will be better in the coached compared to the unguided arm - In terms of pre- to post-treatment changes in pain interference, coached My SCI Toolkit program will be superior to treatment as usual

NCT ID: NCT06098001 Active, not recruiting - Bioavailability Clinical Trials

Bioavailability Study of Hemp Phenolics

Start date: September 15, 2023
Phase: N/A
Study type: Interventional

The aim is to determine the bioavailability of the polyphenol fraction form a commercially available hemp hull fiber at two different amounts in generally healthy adults. Additional objectives include determining specific metabolites produced over a 24 to 48-hour period following the hemp fiber consumption. Subjects will consume a study pudding that will be used to deliver a low and a high dose fiber product. Blood samples will be collected to measure background levels of metabolites. At day 0 participants will consume a low dose study product and day 6 the high dose study product and provide blood samples over an 8 hr period after study product consumption, to be followed by a 24 hr blood sample and 48 hr blood sample. Additionally following the low / high dose study product 24 and 48 h urine samples will be collected.

NCT ID: NCT06097299 Active, not recruiting - Clinical trials for Respiratory Syncytial Virus

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Start date: October 24, 2023
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to <5 years of age and in children at high risk of respiratory syncytial virus (RSV) disease 5 to <18 years of age to inform the dose level selection for the next phase of development (Phase 3).

NCT ID: NCT06097273 Active, not recruiting - Influenza Clinical Trials

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

Start date: October 19, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to <65 years of age (Cohort B).

NCT ID: NCT06096987 Active, not recruiting - Clinical trials for Inflammatory Bowel Diseases

Teen-to-Teen Videos to Improve Electronic Medical Record Portal Knowledge and Personal Health Information Engagement

Start date: July 13, 2021
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare whether videos help teens better understand medical topics. The main questions answered in this trial are: 1. whether videos can improve teen knowledge about electronic medical record portals 2. whether videos can improve teen knowledge about general health issues Participants will answer surveys and watch videos as part of this study.

NCT ID: NCT06096727 Active, not recruiting - Knee Arthroplasty Clinical Trials

The Energize! Study for Adults With Knee Replacement

Start date: October 24, 2023
Phase: N/A
Study type: Interventional

The purpose is to examine the effects of an online physical activity program on moderate to vigorous intensity physical activity, pain, and physical function in adults with knee replacement at 3 months (post-intervention) and 6 months (maintenance).

NCT ID: NCT06095453 Active, not recruiting - Acute Pain Clinical Trials

Evaluation of the Analgesic Efficacy of Multimodal Pain Control Regimens That Aim to Limit the Use of Narcotics in Cholecystectomy and Hernia Repairs

Start date: February 1, 2023
Phase:
Study type: Observational

Subjects were patients of the five surgeons with Surgical Associates of Mansfield (SAM) who underwent an elective or urgent laparoscopic cholecystectomy; or elective or urgent laparoscopic or open hernia repair (inguinal, ventral, or umbilical); and who otherwise met the inclusion criteria. I

NCT ID: NCT06095115 Active, not recruiting - Plaque Psoriasis Clinical Trials

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

ICONIC-LEAD
Start date: October 12, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

NCT ID: NCT06095102 Active, not recruiting - Plaque Psoriasis Clinical Trials

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

ICONIC-TOTAL
Start date: October 12, 2023
Phase: Phase 3
Study type: Interventional

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).

NCT ID: NCT06091995 Active, not recruiting - Clinical trials for Use of Belatacept in Kidney Transplant Patients

Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients With Delayed Graft Function

Start date: August 22, 2022
Phase:
Study type: Observational

Evaluate the impact of one dose of belatacept in patients with Delayed Graft Function(DGF) on their time to renal recovery and corresponding rates of patient and graft survival, rejection, and incidence of BK virus(BKV), Epstein-Barr Virus(EBV) and/or cytomegalovirus (CMV) infections.